Combating Inflammation, Infection and Degenerative Disease with Breakthrough Discovery
We are a clinical stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around plasma gelsolin technology and therapeutics. With our ability to provide a platform to replete plasma gelsolin that has been depleted, we are in a unique position to deliver therapeutics that have the potential to disrupt the way many diseases are treated today.
To address medical issues previously thought to be out of reach -- preventing the damage caused by excess inflammation without suppressing the immune system.
Plasma Gelsolin Addresses Urgent Need
Chronic inflammation plays a central role in some of the most challenging diseases of our time. Restoring the body with a recombinant version of a naturally occurring plasma protein – plasma gelsolin — that becomes depleted in diverse infectious and non-infectious diseases has enormous potential to prevent debilitating and potentially lethal ravages of inflammation without compromising its essential function to fight infection and promote repair. This strategy has consistently reduced morbidity and mortality of animals challenged with acute infections, traumatic and chemical injuries, autoimmune disorders and with insults associated with chronic illnesses.